3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF

NCT02267655 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis

Interventions

DRUG: inhaled Nitric Oxide - 30 mcg/kg IBW/hr
DRUG: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
DRUG: inhaled nitric oxide 75 mcg/kg IBW/hr

Sponsor

Bellerophon